Methsuximide
- Atc Codes:N03AD03
- CAS Codes:77-41-8
- PHARMGKB ID:77-41-8
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Germany: Petinutin.
North America
Canada: Celontin; USA: Celontin.
Drug combinations
Chemistry
Methsuximide: C~12~H~13~NO~2~. Mw: 203.24. (1) 2,5-Pyrrolidinedione,1,3-dimethyl-3-phenyl-, (±)-; (2)(±)-N,2-Dimethyl-2-phenylsuccinimide. CAS-77-41-8.
Pharmacologic Category
Anticonvulsants; Succinimides. (ATC-Code: N03AD03).
Mechanism of action
Increases seizure threshold and suppresses paroxysmal spike-and-wave pattern in absence seizures. Depresses nerve transmission in motor cortex.
Therapeutic use
Control of absence (petit mal) seizures refractory to other drugs.
Pregnancy and lactiation implications
Safe use of methsuximide during pregnancy or lactation not established.
Unlabeled use
Partial complex (psychomotor) seizures.
Contraindications
Hypersensitivity to succinimides or any component of the formulation.
Warnings and precautions
Succinimides associated with severe blood dyscrasias; also with cases of systemic lupus erythematosus. Use with caution in hepatic impairment, and in renal impairment. Effects with other sedative drugs or ethanol may be potentiated. Must be used in combination with other anticonvulsants in both absence and tonic-clonic seizures. May increase tonic-clonic seizures in mixed seizure disorders. Therapy should be withdrawn gradually.